← Eichor
Condition: Trastuzumab Rezetecan Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Trastuzumab Rezetecan

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Subop
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07340398Fosrolapitant Combined With Palonosetron to Prevent Trastuzumab Rezetecan Related CINV
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07726433Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07647263Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expressio
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07704177Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Prol
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07616453Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT07100600Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07670273Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-L
Phase 2 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT07037199Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer
Phase N/A · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT07358182Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metast
Phase 2 · 6 location(s) · Sun Yat-sen University · NCT07241793The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07203729Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer
Phase 4 · 1 location(s) · Peking University People's Hospital · NCT07600164Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST
Phase 2 · 5 location(s) · First Affiliated Hospital of Zhejiang University · NCT07383818Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies
Phase 2 · 1 location(s) · Sheng Zhang · NCT07309770A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
Phase 2 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07497386
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.